linjc16/ctgov huggingface dataset:
Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy

Study Overview
=================
Brief Summary
-----------------
Based on the anatomical features of the anterior Communicating artery complex, the investigators will analyze the outcome of the ACoA aneurysms treated by endovascular therapy. The most common site of intracranial aneurysms is the anterior communicating artery (AcomA). AcomA aneurysms account for approximately one-fourth of all intracranial aneurysms. Recent publications have addressed specifically the endovascular treatment of AcoA aneurysms. Furthermore, detailed anatomic characteristics and the effects of the multiple variations of the anterior communicating artery complex have scarcely been reported. The hemodynamic factors play a fundamental role in the adequate treatment of aneurismal coiling. The objective of our registry is to analyze the impact of morphological configuration of the anterior communicating artery complex and the results of coil embolization in AcoA aneurysms

Official Title
-----------------
Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy

Conditions
-----------------
Intracranial Aneurysm, Anterior Communicating Artery Aneurysm, Cerebral Aneurysm, Aneurysm, Ruptured

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with Anterior Communicating Artery Aneurysm treated with endovascular coiling. Exclusion Criteria: Patients without imaging follow up of at least 12 months after endovascular treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effective Aneurysm Coiling (no residual cerebral aneurysm) |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All Cause Mortality |  | 1 year | 
| Neurological Outcome (classified with the Glasgow Outcome Scale, Rankin Scale) | All patients will be classified with the Glasgow Outcome Scale, Rankin Scale. | 1 year | 
| Procedural device-related serious adverse events |  | 1 year |
Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Study Overview
=================
Brief Summary
-----------------
The purpose of the investigation is to confirm the following under the post-marketing actual use of Forxiga Tablets (hereinafter referred to as Forxiga) Development of ADRs specified as Key Investigation Items and the risk factors Contributing factors possibly having an impact on the safety and efficacy Development of ADRs unexpected from the Precautions for use and ADRs under actual drug use

Official Title
-----------------
Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Conditions
-----------------
Type 2 Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with Forxiga for the first time due to type 2 diabetes mellitus, which is the indication of the drug. Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event incidence |  | from baseline to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes mellitus, Diabetes, Forxiga, Long-term use
Heart Failure Decompensation And In-Hospital Mortality

Study Overview
=================
Brief Summary
-----------------
Background and objectives Heart failure is a leading cause of morbidity and mortality worldwide and it is a major cause of emergency department access for cardiovascular disease patients. Aim of this study is to identify the markers, based on short-term temporal repolarization dispersion, capable to individuate decompensated chronic heart failure (CHF) patients at high mortality risk. Method: We will obtain the following variables from ECG monitor, via mobile phone, during 5-minute recordings in decompensated CHF patients: RR, QT end (QTe), QT peak (QTp) and T peak to T end (Te) and we calculated mean, standard deviation (SD) and normalized index (N).

Official Title
-----------------
Short-Period Temporal Dispersion Repolarization Markers and In-Hospital Mortality in Decompensated Heart Failure: A Pilot Study

Conditions
-----------------
Chronic Heart Failure, Decompensated Heart Failure, Morality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least one symptom or sign compatible with a decompensation and/or a previous documented history of CHF Exclusion Criteria: pneumonia pulmonary embolism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| alive<br> | |
| dead<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | in-hospital mortality in decompensated heart failure patients | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Temporal Dispersion of Repolarization Phase, proBNP, QTVI, QT, Tpeak-Tend
Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients

Study Overview
=================
Brief Summary
-----------------
In growth hormone deficient patients: Determination of endogenous circulating ghrelin levels, ghrelin effects on insulin sensitivity, appetite, energy metabolism, and signal transduction in fat and muscle.

Official Title
-----------------
Effects of Acute Ghrelin Infusion to Growth Hormone Deficient Adults: Growth Hormone and Cortisol Interaction

Conditions
-----------------
Hypopituitarism

Intervention / Treatment
-----------------
* Drug: Human acylated ghrelin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 60 yrs. Verified hypopituitarism Unchanged substitution treatment through 3+ months Unchanged additional medical treatment Oral and written informed consent Exclusion Criteria: Age below 18 or above 60 yrs. Diabetes mellitus body mass index > 30 Fasting hypoglycemia Convulsions Allergy to trial products

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Human acylated ghrelin|5 pmol/kg body weight per min|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endogenous serum ghrelin levels |  | Same day as intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity, appetite, metabolism, intracellular signal transduction |  | Same day as intervention |
Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

Study Overview
=================
Brief Summary
-----------------
Unfractionated heparin is most common in the anticoagulation management of V-V ECMO. However, many side effects of unfractionated heparin, such as HIT, antithrombin deficiency, etc seriously affects the prognosis of patients. Argatroban is kind of direct thrombin inhibitors, which could be used used as an alternative anticoagulant of unfractionated heparin when HIT or antithrombin deficiency, etc. At present, there is no power enough evidence for the application of argatroban in V-V ECMO. This study aims to evaluat the safety and effectiveness of argatroban in the anticoagulation management of V-V ECMO compared with unfractionated heparin.

Official Title
-----------------
Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO: A Randomized Controlled Study

Conditions
-----------------
Respiratory Failure

Intervention / Treatment
-----------------
* Drug: Argatroban
* Drug: unfractionated heparin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age older than 18 years old; received V-V ECMO because of sevever respiratory failure Exclusion Criteria: anticoagulant contraindications; Confirmed or suspected, or previously diagnosed with heparin induced thrombocytopenia; Cerebral infarction or suspected patients; Patients with severe liver dysfunction; Allergic to heparin or argatroban; hemophilia; Unwilling or unable to complete the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: argatroban group<br>Patients received argatroban for anticoagulation during V-V ECMO. | Drug: Argatroban<br>* Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.<br>* Other names: Novastan;|
| Active Comparator: UFH group<br>Patients received UFH for anticoagulation during V-V ECMO. | Drug: unfractionated heparin<br>* unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of ECMO related thrombotic events | the incidence of ECMO related thrombotic events, such as membrane oxygenator or tube thrombosis. | 14 days |
Assessment of Oral Health Status of Patients in Pediatric Intensive Care Units

Study Overview
=================
Brief Summary
-----------------
The research is a descriptive study designed to evaluate the oral health status of hospitalized children in pediatric intensive care units. The research was conducted between June 2021 and September 2021 in pediatric intensive care units in Izmir province. The patients were included in the study by using the cluster sampling method in the selection of the sample (n=88). Patient Identification Information Form and Oral Assessment Guide (OAG) were used for oral health assessment of patients. It was taken written consents from the hospitals where the research was carried out and from the relatives of the patients

Official Title
-----------------
Assessment of Oral Health Status of Patients in Pediatric Intensive Care Units

Conditions
-----------------
Assessment of Oral Health Status of Patients in Pediatric Intensive Care Units

Intervention / Treatment
-----------------
* Procedure: Assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being treated in the PICU Parent's consent to participate in the study Exclusion Criteria: Applying non-invasive ventilation therapy

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observed<br>Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide. Patient's age, gender, day of hospitalization in pediatric intensive care units, medical diagnosis/diagnoses, presence of chronic disease, state of consciousness, body temperature, oral care application method, oral care application frequency, oral care product used, amount taken/extracted, drugs used, albumin and haemoglobin data on values were obtained from the observation form of the patient. | Procedure: Assessment<br>* Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessing oral status of children in pediatric intensive care unit | Oral health of the patient was evaluated using a flashlight and tongue depressor | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric intensive care unit, Oral health, Oral care, Oral health assessment
Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer

Study Overview
=================
Brief Summary
-----------------
Anastomotic leakage is a serious complication after LAR with high morbidity and mortality rates. Early diagnosis and treatment is mandatory. The primary aim of the present study is to investigate the clinical use of peritoneal microdialysis and whether is able to detect anastomotic leakage prior to clinical symptoms.

Detailed Description
-----------------
Patients undergoing LAR for rectum cancer is subjected to peritoneal microdialyses during the postoperative period until the 7. postoperative day. Samples are collected every 4-hour. Samples will be analyzed continuously but the results will not be included in the clinical evaluation of the patient. Before removing the microdialysis catheter a CT whit rectal enema is preformed. Every day the patient will be evaluated whit a standardised clinical scoring system with attention at anastomotic leakage. A total of 150 patients will be included in this study. The results of the peritoneal microdialyses will be compared with the clinical scorings system in each patient. The results form the uncomplicated courses will be used to define the normal variations in peritoneal microdialysis. This will be compared to results from patients with various complications. The study is approved by the local scientific ethical committee No. ------

Official Title
-----------------
Intraperitoneal Microdialysis Monitoring of Patients During the Early Postoperative Period After LAR With Reference to Early Diagnosis of Anastomotic Leakage Ore Other Complications

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Procedure: Peritoneal Microdialysis, CT-scan, leakage scoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological verified cancer The cancer must be located in rectum maximum of 15 cm. Diverting stoma is allowed Perioperative radio-chemotherapy is allowed Exclusion Criteria: Disseminated cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Microdialysis<br> | Procedure: Peritoneal Microdialysis, CT-scan, leakage scoring<br>* Peritoneal microdialysis CT-scan before discharge Leakage scoring daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Significant elevated peritoneal microdialysis parameter like lactate and L/P-ratio |  | Clinically complications with in 30th days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anastomotic leakage after LAR
Changing of Prostate Specific Antigen Value in Patients With Covid-19

Study Overview
=================
Brief Summary
-----------------
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19. In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Detailed Description
-----------------
Patients with positive PCR test results were included in the study. The age of the patient and urea, leukocyte, hemoglobin, platelet, urea, and creatinine values of the patients were recorded. Urinalysis and urine culture were taken from all patients. Acute phase reactants such as sedimentation, C-reaktif protein (CRP), ferritin, and fibrinogen were measured both at the time the patients applied and three weeks after the patient recovered. PSA and free PSA were also measured in the same way. Patients whose symptoms improved and the PCR test result was negative were considered as recovered.

Official Title
-----------------
Changing of PSA With Covid-19

Conditions
-----------------
Prostate Specific Antigen, Covid19

Intervention / Treatment
-----------------
* Other: PSA value


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male patients (>45 and <70 years of age) positive PCR test results were included in the study Exclusion Criteria: The patients <45 and >70 years of age who described lower urinary tract symptoms who had urinary tract infection who a history of prostate biopsy and previous high level of PSA who history of prostatitis were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: We measured PSA value during and after Covid-19 infection
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Covid-19 group<br>We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test | Other: PSA value<br>* We measure PSA value during and after covid-19 infection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PSA value | prostate specific antigen | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ferritin, CRP |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid-19, Prostate cancer, Prostate Specific Antigen
Congestive Heart Failure Surgical Treatmment With Autologous Stem Cell Therapy

Study Overview
=================
Brief Summary
-----------------
This research study was designed to test the safety and effectiveness of autologous stem cell graft in the myocardium of patients with refractory Congestive Heart Failure (CHF) with ischemic etiology. Cellular implantation will take place during off-pump revascularization surgery or during an ad hoc procedure using a mini-thoracotomy access.

Detailed Description
-----------------
Primary target: determine the safety of introducing CD 34+ autologous progenitor cells (centrally grafted or mobilized in peripheral blood) in the myocardium of ischemic cardiac disease patients. Secondary target: determine clinical effects of grafted cells on remodeling pathology.

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Procedure: intramiocardiac autograft of autologous stem cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Age >18 y/o CHF with EF > 35% Bilirubinemia, serum transaminase> 2.5 times normal max level Creatininemia > 2.5 times max level NYHA Class > 3 Negative pregnancy test (for women in fertile age) Exclusion criteria Impossibility to harvest the bone marrow Pregnancy or breast-feeding History of malignant neoplasia in the 5-year period before the study (save for in-situ carcinoma of the cervix treated successfully and skin tumors - not melanomas) Incapability or unwillingness to comply with the envisaged treatment protocol, follow-up, or tests.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: intramiocardiac autograft of autologous stem cells|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary target: determine the safety of introducing CD 34+ autologous progenitor cells (centrally grafted or mobilized in peripheral blood) in the myocardium of ischemic cardiac disease patients. |  | 1 YEAR | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary target: determine clinical effects of grafted cells on remodeling pathology. |  | 1 YEAR |